Actively Recruiting
Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)
Led by Commissariat A L'energie Atomique · Updated on 2025-02-14
240
Participants Needed
1
Research Sites
257 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spirometry is now the gold standard technique for assessing lung function in humans. From the shape of a flow-volume curve measured while the patient, trained by the practitioner, performs forced breaths, the forced vital capacity (FVC) and the forced expiratory volume in one second (FEV1) can be deduced and the pulmonologist is able to detect and characterize respiratory diseases as well as to evaluate current treatments. This technique is non-invasive and simple. It is widely available, robust, reproducible and sensitive to intervention. However, it requires proactive cooperation from the patient and only measures global pulmonary ventilation, without locoregional information. An innovative strategy and an original study framework have been developed in the BioMaps laboratory to establish local maps of flow-volume curves across the lung and to jointly analyze ventilatory function and mechanical behavior at any point in the lung: 3D magnetic resonance spirometry. As respiratory mechanics fundamentally supports ventilatory function, this technique should open a new avenue to non-invasively explore lung function while providing a better diagnosis of regional lung diseases.
CONDITIONS
Official Title
Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand the study and give informed consent
- Ability to remain still in an MRI scanner in supine position for the scan duration
- Healthy volunteers aged 18-45 years without known lung diseases and non-smokers
- Asthma patients aged 18-80 years with moderate or severe asthma diagnosed for at least 6 months and non-smokers/non-vapourists
- COPD patients aged 40-80 years with moderate to severe COPD
- Bilateral lung transplant patients aged 18-90 years with or without bronchiolitis obliterans syndrome (BOS) meeting specific lung function and imaging criteria
You will not qualify if you...
- Presence of visible lung parenchymal opacities on CT scan (mixed RAS/CLAD)
- Significant bronchial stenosis requiring endoscopic treatment
- Diaphragmatic impairment confirmed by sniff test or ultrasound
- Current smokers or vapour users (for asthma and healthy volunteers)
- Inability to remain motionless during MRI scans
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CEA | Service Hospitalier Fréderic Joliot
Orsay, France, France, 91401
Actively Recruiting
Research Team
M
MARTINS Bernadette
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here